LIGAND PHARMACEUTICALS (LGND)
US53220K5048 - Common Stock
| TTM (2024-3-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
| Net Income | 96.43M | 52.15M | -33.40M | 57.10M | -3.00M | |||
| Depreciation Amortization | 35.79M | 36.52M | 51.50M | 51.10M | 25.70M | |||
| Income Taxes - Deferred | 22.44M | 11.70M | 20.70M | -8.60M | -19.10M | |||
| Change In Working Capital | -34.06M | -34.40M | 65.70M | -52.20M | -10.10M | |||
| Interest Paid | 347.00K | 288.00K | 1.40M | 3.00M | 4.50M | |||
| Taxes Paid | N/A | 8.77M | 11.60M | 3.70M | 2.10M | |||
| Other non cash items | -86.15M | -16.39M | 33.30M | 31.40M | 61.00M | |||
| OPERATING CASH FLOW | 34.41M | 49.58M | 137.90M | 78.80M | 54.60M | |||
| CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||
| Capital Expenditure | -61.96M | -64.25M | -17.90M | -8.80M | -4.50M | |||
| Other Investing Activity | 35.90M | 52.57M | 181.50M | 39.30M | 236.10M | |||
| INVESTING CASH FLOW | -25.96M | -11.68M | 163.60M | 30.50M | 231.60M | |||
| CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||
| Debt Issued/Reduced | -76.90M | -76.90M | -261.00M | -164.90M | -231.80M | |||
| Stock Issued/Repurchased | 34.35M | 22.45M | 3.20M | 15.30M | -75.00M | |||
| Other Financing Activity | -4.41M | -5.50M | -18.20M | 11.90M | -3.80M | |||
| FINANCING CASH FLOW | -46.97M | -59.95M | -276.00M | -137.80M | -310.50M | |||
| Exchange Rate Effect | N/A | N/A | N/A | 0.00 | 0.00 | |||
| CHANGE IN CASH | -38.51M | -22.05M | 25.50M | -28.50M | -24.30M | |||
| FREE CASH FLOW | ||||||||
| Operating Cash Flow | 34.41M | 49.58M | 137.90M | 78.80M | 54.60M | |||
| Capital Expenditure | -61.96M | -64.25M | -17.90M | -8.80M | -4.50M | |||
| FREE CASH FLOW | -27.55M | -14.68M | 120.00M | 70.00M | 50.10M | |||
All data in USD